Apimeds Pharmaceuticals US (APUS) Shares Outstanding (Diluted Average) (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Shares Outstanding (Diluted Average) of $10.9 million for Q4 2025, up 37.68% on a YoY basis from $7.9 million in Q4 2024, and down 13.47% quarter-over-quarter from $12.6 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Shares Outstanding (Diluted Average) (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Shares Outstanding (Diluted Average) for 2 years, with the latest figure at $10.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 37.68% year-over-year to $10.9 million; the trailing twelve-month figure through Dec 2025 stood at $10.9 million (up 37.68% YoY), and the FY2025 full-year result was $10.9 million, up 37.68% from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 stood at $10.9 million, down from $12.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $12.6 million in Q3 2025, with the low at $7.9 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Diluted Avg.) (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 1.18 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 422.40 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 47.20 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 103.40 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 506.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 228.36 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 10.88 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 10.88 Mn
Sep 30, 2025 12.58 Mn
Jun 30, 2025 10.37 Mn
Mar 31, 2025 7.90 Mn
Dec 31, 2024 7.90 Mn
Sep 30, 2024 7.90 Mn
Jun 30, 2024 7.90 Mn
Mar 31, 2024 7.90 Mn